カテゴリー： 世界, 医療/バイオ, Grand View Research

世界のブランドジェネリック市場2023-2030：薬物クラス別（アルキル化剤、代謝拮抗剤、抗高血圧剤）、用途別、投与経路別、流通チャネル別、地域別

【英語タイトル】Branded Generics Market Size, Share & Trends Analysis By Drug Class (Alkylating Agents, Antimetabolites, Anti-Hypertensive), By Application, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23JUN024）・商品コード：GRV23JUN024
・発行会社（調査会社）：Grand View Research
・発行日：2023年5月8日
・ページ数：155
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Grand View Research社の市場調査書によると、世界のブランドジェネリック市場規模が、予測期間中に年平均5.7％増加し、2030年までに3,759.5億ドルへ達すると見込まれています。本調査書では、ブランドジェネリックの世界市場を調査対象とし、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、薬剤クラス別（アルキル化剤、代謝拮抗剤、ホルモン剤、抗高血圧剤、その他）分析、用途別（腫瘍、心血管疾患、神経疾患、急性・慢性疼痛、その他）分析、投与経路別（外用、経口、非経口、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別（北米、ヨーロッパ、アジア太平洋中南米、中東・アフリカ）分析、競合分析などについて調査・分析し、まとめています。なお、こちらに掲載されている企業情報には、TEVA PHARMACEUTICAL INDUSTRIES LTD.、LUPIN、SANOFI、SUN PHARMACEUTICAL INDUSTRIES, LTD.、DR. REDDY’S LABORATORIES LTD.、ENDO INTERNATIONAL PLC、GLAXOSMITHKLINE PLC (GSK)、PFIZER, INC.、VIATRIS, INC.、APOTEX, INC.などが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・世界ブランドジェネリックの市場規模：薬剤クラス別
- アルキル化剤の市場規模
- 代謝拮抗剤の市場規模
- ホルモン剤の市場規模
- 抗高血圧剤の市場規模
- その他ブランドジェネリックの市場規模
・世界ブランドジェネリックの市場規模：用途別
- 腫瘍における市場規模
- 心血管疾患における市場規模
- 神経疾患における市場規模
- 急性・慢性疼痛における市場規模
- その他用途における市場規模
・世界ブランドジェネリックの市場規模：投与経路別
- 外用における市場規模
- 経口における市場規模
- 非経口における市場規模
- その他投与経路における市場規模
・世界ブランドジェネリックの市場規模：流通チャネル別
- 病院薬局における市場規模
- 小売薬局における市場規模
- オンライン薬局における市場規模
・世界ブランドジェネリックの市場規模：地域別
- 北米のブランドジェネリック市場規模
- ヨーロッパのブランドジェネリック市場規模
- アジア太平洋のブランドジェネリック市場規模
- 中南米のブランドジェネリック市場規模
- 中東・アフリカのブランドジェネリック市場規模
・競合分析

ブランドジェネリック市場の成長と動向

Grand View Research, Inc.の最新レポートによると、ブランドジェネリックの世界市場規模は2030年までに3,759億5,000万米ドルに達し、予測期間中の年平均成長率は5.7%に達すると予測されています。主要製品の特許切れ、慢性疾患の有病率の上昇、ジェネリック医薬品の高い普及率、全体的な医療費削減を目的としたジェネリック医薬品普及への政府の取り組みなどが主な成長促進要因となっています。

ブランド製品の特許切れは主に業界の成長を促進します。RevlimidやAlimtaなどの薬剤は、1ヵ月に500米ドルもかかることがあり、慢性疾患を患う患者の全体的な医療支出や経済的負担に影響を与えています。Eli Lilly & Companyの Alimtaは、2022年5月までに特許保護が切れると予想されています。このような製品特許の失効は、ジェネリック医薬品やバイオシミラーメーカーにチャンスをもたらします。

しかし、ここ数年、ジェネリック医薬品のANDA承認件数は着実に減少しています。ANDA承認件数は2019年の1,014件から2020年には948件に減少し、さらに2021年には776件に減少していることが確認できます。このような要因は、今後数年間、業界の成長を鈍化させる可能性があります。

糖尿病、高血圧、肥満などの慢性疾患に罹患しやすい高齢者人口の増加と相まって、感染症および非感染症の負担が増加していることは、業界の成長にプラスの影響を与えると予想されます。NCBIの論文によると、2021年に糖尿病に苦しむ患者は世界で5億3,700万人に上ります。

COVID-19のパンデミックは、ブランドジェネリック医薬品分野に中程度の影響を与えました。パンデミックを抑制するための封鎖状況や厳しい政府規制により、パンデミックの初期段階では医薬品供給の停滞と混乱が見られ、更に規制当局の動きも、この分野における償還の決定や新製品の承認に影響を与えました。しかし、ほとんどの国で市場は2020年末までにペースを取り戻しました。

各社は製品ポートフォリオを強化するため、新規製品を投入しています。2022年3月、Viatris社はAstraZeneca社のCOPD治療薬シムビコートの初のジェネリック医薬品であるBreynaの承認を米国FDAから取得しました。さらに2019年2月、Mylan N.V.は、慢性閉塞性肺疾患（COPD）または喘息患者の治療薬として、ADVAIR DISKUS（フルチカゾンプロピオン酸エステルおよびサルメテロール吸入粉末）の初のジェネリック医薬品をWixela Inhubのブランドで発売しました。このブランドジェネリックは、先発品より70%安いとしています。

ブランドジェネリック市場レポートハイライト

– 心血管疾患の負担増に伴う需要の増加やジェネリック医薬品の普及拡大などの要因により、2022年の売上高シェアは降圧薬クラスが15.67%と大きく貢献しました。

– 経口剤セグメントは2022年に59.3%と最大の売上シェアを占めました。これは、投与が容易で看護の必要がないなど経口剤にはいくつかの利点があり、患者の受容性とコンプライアンスの向上につながるためです。

– 小売薬局の流通チャネルは、小売薬局チェーンの存在感の高まりや、これらのチェーンと既存の病院との提携などの要因により、2022年に58.6％と市場の大きなシェアを占めました。

– アジア太平洋地域は、主要プレイヤーの存在、処方率の高さとブランドジェネリックへの嗜好性、慢性疾患の有病率の増加、高齢者人口の増加などにより、予測期間中に最も高いCAGRで成長すると予想されます。

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.3.6 List Of Primary Sources
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country – wise market estimation using bottom – up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Abbreviations
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
1.11.3 Objective 3
1.11.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Market Variables, Trends, & Scope
3.1 Penetration and Growth Prospect Mapping
3.2 Regulatory Landscape
3.3 Branded Generics Market Dynamics
3.3.1 Market Driver Analysis
3.3.2 Market Restraint Analysis
3.4 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
3.5 Porter’s Five Forces Analysis
3.6 User Perspective Analysis
Chapter 4 Branded Generics Market – Segment Analysis, By Drug Class, 2018 – 2030 (USD Billion)
4.1 Branded Generics Market: Drug Class Movement Analysis
4.2 Alkylating Agents
4.2.1 Alkylating Agents Market Estimates and Forecast, 2018 – 2030 (USD Billion)
4.3 Antimetabolites
4.3.1 Antimetabolites Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
4.4 Hormones
4.4.1 Hormones Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
4.5 Anti – Hypertensive
4.5.1 Anti – Hypertensive Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
4.6 Lipid Lowering Drugs
4.6.1 Lipid Lowering Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
4.7 Antidepressants
4.7.1 Antidepressants Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
4.8 Antipsychotics
4.8.1 Anti – Psychotics Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
4.9 Antiepileptics
4.9.1 AntiEpileptics Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
4.10 Others
4.10.1 Others Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
Chapter 5 Branded Generics Market – Segment Analysis, By Application, 2018 – 2030 (USD Billion)
5.1 Branded Generics Market: Application Movement Analysis
5.2 Oncology
5.2.1 Oncology Market Estimates and Forecast, 2018 – 2030 (USD Billion)
5.3 Cardiovascular Diseases
5.3.1 Cardiovascular Diseases Market Estimates and Forecast, 2018 – 2030 (USD Billion)
5.4 Neurological Diseases
5.4.1 Neurological Diseases Market Estimates and Forecast, 2018 – 2030 (USD Billion)
5.5 Acute & Chronic Pain
5.5.1 Acute & Chronic Pain Market Estimates and Forecast, 2018 – 2030 (USD Billion)
5.6 Gastrointestinal Diseases
5.6.1 Gastrointestinal Diseases Market Estimates and Forecast, 2018 – 2030 (USD Billion)
5.7 Dermatological Diseases
5.7.1 Dermatological Diseases Market Estimates and Forecast, 2018 – 2030 (USD Billion)
5.8 Others
5.8.1 Others Market Estimates and Forecast, 2018 – 2030 (USD Billion)
Chapter 6 Branded Generics Market – Segment Analysis, By Route of Administration, 2018 – 2030 (USD Billion)
6.1 Branded Generics Market: Route of Administration Movement Analysis
6.2 Topical
6.2.1 Topical Market Estimates and Forecast, 2018 – 2030 (USD Billion)
6.3 Oral
6.3.1 Oral Market Estimates and Forecast, 2018 – 2030 (USD Billion)
6.4 Parenteral
6.4.1 Parenteral Market Estimates and Forecast, 2018 – 2030 (USD Billion)
6.5 Others
6.5.1 Others Market Estimates and Forecast, 2018 – 2030 (USD Billion)
Chapter 7 Branded Generics Market – Segment Analysis, By Distribution Channel, 2018 – 2030 (USD Billion)
7.1 Branded Generics Market: Distribution Channel Movement Analysis
7.2 Hospital Pharmacy
7.2.1 Hospital Pharmacy Market Estimates and Forecast, 2018 – 2030 (USD Billion)
7.3 Retail Pharmacy
7.3.1 Retail Pharmacy Market Estimates and Forecast, 2018 – 2030 (USD Billion)
7.4 Online Pharmacy
7.4.1 Online Pharmacy Market Estimates and Forecast, 2018 – 2030 (USD Billion)
Chapter 8 Branded Generics Market – Segment Analysis, By Region, 2018 – 2030 (USD Billion)
8.1 Branded Generics Market, Market Share by Region, 2022 & 2030
8.2 Branded Generics Market: Regional Outlook
8.3 North America
8.2.1 North America Branded Generics Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.2.2 U.S.
8.2.2.1 Key Country Dynamics
8.2.2.2 U.S. Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.2.2.3 Target Disease Prevalence
8.2.2.5 Competitive Scenario
8.2.2.6 Regulatory Framework
8.2.2.7 Reimbursement Scenario
8.2.3 Canada
8.2.3.1 Key Country Dynamics
8.2.3.2 Canada Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.2.3.3 Target Disease Prevalence
8.2.3.4 Competitive Scenario
8.2.3.5 Regulatory Framework
8.2.3.6 Reimbursement Scenario
8.3 Europe
8.3.1 Europe Branded Generics Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.2 U.K.
8.3.2.1 Key Country Dynamics
8.3.2.2 U.K. Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.3.2.3 Target Disease Prevalence
8.3.2.4 Competitive Scenario
8.3.2.5 Regulatory Framework
8.3.2.6 Reimbursement Scenario
8.3.3 Germany
8.3.3.1 Key Country Dynamics
8.3.3.2 Germany Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.3.3.3 Target Disease Prevalence
8.3.3.4 Competitive Scenario
8.3.3.5 Regulatory Framework
8.3.3.6 Reimbursement Scenario
8.3.4 France
8.3.4.1 Key Country Dynamics
8.3.4.2 France Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.3.4.3 Target Disease Prevalence
8.3.4.4 Competitive Scenario
8.3.4.5 Regulatory Framework
8.3.4.6 Reimbursement Scenario
8.3.5 Italy
8.3.5.1 Key Country Dynamics
8.3.5.2 Italy Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.3.5.3 Target Disease Prevalence
8.3.5.4 Competitive Scenario
8.3.5.5 Regulatory Framework
8.3.5.6 Reimbursement Scenario
8.3.6 Spain
8.3.6.1 Key Country Dynamics
8.3.6.2 Spain Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.3.6.3 Target Disease Prevalence
8.3.6.4 Competitive Scenario
8.3.6.5 Regulatory Framework
8.3.6.6 Reimbursement Scenario
8.3.7 Denmark
8.3.8.1 Key Country Dynamics
8.3.8.2 Denmark Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.3.8.3 Target Disease Prevalence
8.3.8.4 Competitive Scenario
8.3.8.5 Regulatory Framework
8.3.8.6 Reimbursement Scenario
8.3.8 Sweden
8.3.8.1 Key Country Dynamics
8.3.8.2 Sweden Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.3.8.3 Target Disease Prevalence
8.3.8.4 Competitive Scenario
8.3.8.5 Regulatory Framework
8.3.8.6 Reimbursement Scenario
8.3.9 Norway
8.3.8.1 Key Country Dynamics
8.3.8.2 Norway Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.3.8.3 Target Disease Prevalence
8.3.8.4 Competitive Scenario
8.3.8.5 Regulatory Framework
8.3.8.6 Reimbursement Scenario
8.4 Asia Pacific
8.4.1 Asia Pacific Branded Generics Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4.2 JAPAN
8.4.2.1 Key Country Dynamics
8.4.2.2 Japan Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.4.2.3 Target Disease Prevalence
8.4.2.4 Competitive Scenario
8.4.2.5 Regulatory Framework
8.4.2.6 Reimbursement Scenario
8.4.3 China
8.4.3.1 Key Country Dynamics
8.4.3.2 China Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.4.3.3 Target Disease Prevalence
8.4.3.4 Competitive Scenario
8.4.3.5 Regulatory Framework
8.4.3.6 Reimbursement Scenario
8.4.4 india
8.4.4.1 Key Country Dynamics
8.4.4.2 India Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.4.4.3 Target Disease Prevalence
8.4.4.4 Competitive Scenario
8.4.4.5 Regulatory Framework
8.4.4.6 Reimbursement Scenario
8.4.5 Australia
8.4.5.1 Key Country Dynamics
8.4.5.2 Australia Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.4.5.3 Target Disease Prevalence
8.4.5.4 Competitive Scenario
8.4.5.5 Regulatory Framework
8.4.5.6 Reimbursement Scenario
8.4.6 South Korea
8.4.6.1 Key Country Dynamics
8.4.6.2 South Korea Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.4.6.3 Target Disease Prevalence
8.4.6.4 Competitive Scenario
8.4.6.5 Regulatory Framework
8.4.6.6 Reimbursement Scenario
8.4.7 Thailand
8.4.8.1 Key Country Dynamics
8.4.8.2 Thailand Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.4.8.3 Target Disease Prevalence
8.4.8.4 Competitive Scenario
8.4.8.5 Regulatory Framework
8.4.8.6 Reimbursement Scenario
8.5 Latin America
8.5.1 Latin America Branded Generics Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.5.2 Brazil
8.5.2.1 Key Country Dynamics
8.5.2.2 Brazil Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.5.2.3 Target Disease Prevalence
8.5.2.4 Competitive Scenario
8.5.2.5 Regulatory Framework
8.5.2.6 Reimbursement Scenario
8.5.3 Mexico
8.5.3.1 Key Country Dynamics
8.5.3.2 Mexico Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.5.3.3 Target Disease Prevalence
8.5.3.4 Competitive Scenario
8.5.3.5 Regulatory Framework
8.5.3.6 Reimbursement Scenario
8.5.4 Argentina
8.5.4.1 Key Country Dynamics
8.5.4.2 Argentina Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.5.4.3 Target Disease Prevalence
8.5.4.4 Competitive Scenario
8.5.4.5 Regulatory Framework
8.5.4.6 Reimbursement Scenario
8.6 Middle East and Africa
8.6.1 Middle East and Africa Branded Generics Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.6.1.1 Target Disease Prevalence
8.6.1.2 Competitive Scenario
8.6.1.3 Regulatory Framework
8.6.1.4 Reimbursement Scenario
8.6.2 South Africa
8.6.2.1 Key Country Dynamics
8.6.2.2 South Africa Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.6.2.3 Target Disease Prevalence
8.6.2.4 Competitive Scenario
8.6.2.5 Regulatory Framework
8.6.2.6 Reimbursement Scenario
8.6.3 Saudi Arabia
8.6.3.1 Key Country Dynamics
8.6.3.2 Saudi Arabia Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.6.3.3 Target Disease Prevalence
8.6.3.4 Competitive Scenario
8.6.3.5 Regulatory Framework
8.6.3.6 Reimbursement Scenario
8.6.4 UAE
8.6.4.1 Key Country Dynamics
8.6.4.2 UAE Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.6.4.3 Target Disease Prevalence
8.6.4.4 Competitive Scenario
8.6.4.5 Regulatory Framework
8.6.4.6 Reimbursement Scenario
8.6.5 KUWAIT
8.6.5.1 Key Country Dynamics
8.6.5.2 Kuwait Branded Generics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
8.6.5.3 Target Disease Prevalence
8.6.5.4 Competitive Scenario
8.6.5.5 Regulatory Framework
8.6.5.6 Reimbursement Scenario
Chapter 9 Branded Generics Market – Competitive Analysis
9.1 Company Categarization
9.2 Stragy Mapping
9.2.1 New Product Launch
9.2.2 Partnership
9.2.3 Acquisition
9.2.4 Collaboration
9.2.5 Funding
9.3 KEY Company Market Share Analysis, 2022
9.4 Company PROFILES
9.4.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
9.4.1.1 Company Overview
9.4.1.2 Financial Performance
9.4.1.3 Product Benchmarking
9.4.1.4 Strategic Initiatives
9.4.2 LUPIN
9.4.2.1 Company Overview
9.4.2.2 Financial Performance
9.4.2.3 Product Benchmarking
9.4.2.4 Strategic Initiatives
9.4.3 SANOFI
9.4.3.1 Company Overview
9.4.3.2 Financial Performance
9.4.3.3 Product Benchmarking
9.4.3.4 Strategic Initiatives
9.4.4 SUN PHARMACEUTICAL INDUSTRIES, LTD.
9.4.4.1 Company Overview
9.4.4.2 Financial Performance
9.4.4.3 Product Benchmarking
9.4.4.4 Strategic Initiatives
9.4.5 DR. REDDY’S LABORATORIES LTD.
9.4.5.1 Company Overview
9.4.5.2 Financial Performance
9.4.5.3 Product Benchmarking
9.4.5.4 Strategic Initiatives
9.4.6 ENDO INTERNATIONAL PLC
9.4.6.1 Company Overview
9.4.6.2 Financial Performance
9.4.6.3 Product Benchmarking
9.4.6.4 Strategic Initiatives
9.4.7 GLAXOSMITHKLINE PLC (GSK)
9.4.7.1 Company Overview
9.4.7.2 Financial Performance
9.4.7.3 Product Benchmarking
9.4.7.4 Strategic Initiatives
9.4.8 PFIZER, INC.
9.4.8.1 Company Overview
9.4.8.2 Financial Performance
9.4.8.3 Product Benchmarking
9.4.8.4 Strategic Initiatives
9.4.9 VIATRIS, INC.
9.4.9.1 Company Overview
9.4.9.2 Financial Performance
9.4.9.3 Product Benchmarking
9.4.9.4 Strategic Initiatives
9.4.10 APOTEX, INC.
9.4.10.1 Company Overview
9.4.10.2 Product Benchmarking
9.4.10.3 Strategic Initiatives

List of Tables

Table 1 Global Branded Generics Market, By Region, 2018 - 2030 (USD Billion)
Table 2 Global Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 3 Global Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 4 Global Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 5 Global Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 6 North America Branded Generics Market, By Country, 2018 - 2030 (USD Billion)
Table 7 North America Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 8 North America Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 9 North America Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 10 North America Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 11 U.S. Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 12 U.S. Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 13 U.S. Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 14 U.S. Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 15 Canada Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 16 Canada Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 17 Canada Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 18 Canada Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 19 Europe Branded Generics Market, By Country, 2018 - 2030 (USD Billion)
Table 20 Europe Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 21 Europe Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 22 Europe Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 23 Europe Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 24 UK Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 25 UK Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 26 UK Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 27 UK Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 28 Germany Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 29 Germany Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 30 Germany Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 31 Germany Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 32 France Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 33 France Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 34 France Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 35 France Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 36 Italy Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 37 Italy Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 38 Italy Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 39 Italy Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 40 Spain Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 41 Spain Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 42 Spain Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 43 Spain Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 44 Denmark Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 45 Denmark Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 46 Denmark Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 47 Denmark Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 48 Sweden Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 49 Sweden Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 50 Sweden Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 51 Sweden Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 52 Norway Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 53 Norway Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 54 Norway Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 55 Norway Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 56 Asia Pacific Branded Generics Market, By Country, 2018 - 2030 (USD Billion)
Table 57 Asia Pacific Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 58 Asia Pacific Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 59 Asia Pacific Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 60 Asia Pacific Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 61 Japan Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 62 Japan Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 63 Japan Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 64 Japan Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 65 China Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 66 China Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 67 China Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 68 China Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 69 India Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 70 India Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 71 India Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 72 India Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 73 Australia Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 74 Australia Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 75 Australia Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 76 Australia Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 77 South Korea Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 78 South Korea Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 79 South Korea Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 80 South Korea Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 81 Thailand Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 82 Thailand Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 83 Thailand Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 84 Thailand Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 85 Latin America Branded Generics Market, By Country, 2018 - 2030 (USD Billion)
Table 86 Latin America Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 87 Latin America Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 88 Latin America Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 89 Latin America Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 90 Brazil Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 91 Brazil Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 92 Brazil Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 93 Brazil Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 94 Mexico Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 95 Mexico Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 96 Mexico Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 97 Mexico Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 98 Argentina Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 99 Argentina Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 100 Argentina Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 101 Argentina Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 102 Middle East & Africa Branded Generics Market, By Country, 2018 - 2030 (USD Billion)
Table 103 Middle East & Africa Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 104 Middle East & Africa Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 105 Middle East & Africa Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 106 Middle East & Africa Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 107 South Africa Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 108 South Africa Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 109 South Africa Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 110 South Africa Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 111 Saudi Arabia Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 112 Saudi Arabia Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 113 Saudi Arabia Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 114 Saudi Arabia Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 115 UAE Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 116 UAE Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 117 UAE Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 118 UAE Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)
Table 119 Kuwait Branded Generics Market, By Drug Class, 2018 - 2030 (USD Billion)
Table 120 Kuwait Branded Generics Market, By Application, 2018 - 2030 (USD Billion)
Table 121 Kuwait Branded Generics Market, By Route of Administration, 2018 - 2030 (USD Billion)
Table 122 Kuwait Branded Generics Market, By Distribution Channel, 2018 - 2030 (USD Billion)

★調査レポート[世界のブランドジェネリック市場2023-2030：薬物クラス別（アルキル化剤、代謝拮抗剤、抗高血圧剤）、用途別、投与経路別、流通チャネル別、地域別] (コード：GRV23JUN024)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のブランドジェネリック市場2023-2030：薬物クラス別（アルキル化剤、代謝拮抗剤、抗高血圧剤）、用途別、投与経路別、流通チャネル別、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のピーナッツアレルギー治療市場2023-2030：薬物クラス別（抗ヒスタミン薬、エピネフリン）、投与経路別、流通チャネル別、地域別
  • 世界のジェネリック医薬品市場2023-2030：種類別（一般ジェネリック、特殊ジェネリック、バイオシミラー）、投与経路別、製品別、用途別、流通チャネル別、地域別
  • 世界の抗生物質耐性市場2023-2030：疾患別（cUTI、CDI）、病原体別、薬物クラス別（オキサゾリジノン、リポグリコペプチド）、作用機序別、流通チャネル別、地域別
  • 世界の降圧薬市場2024-2030：薬剤クラス別（利尿薬、ACE阻害薬）、種類別（一次、二次）、投与経路別、流通チャネル別、地域別
  • 世界の解毒薬市場2024-2030：種類別（化学的解毒剤、物理的解毒剤、薬理学的解毒剤）、投与経路別、流通チャネル別、エンドユーザー別、地域別
  • 世界の化学療法治療市場（～2030年）：薬剤別（抗腫瘍抗生物質、トポイソメラーゼ阻害剤、アルキル化剤、分裂阻害剤、代謝拮抗剤、その他）、薬剤経路別、投与量別、エンドユーザー別、地域別
  • 世界の筋弛緩剤市場2023-2030：薬剤種類別（骨格筋弛緩剤、顔面筋弛緩剤）、投与経路別、流通チャネル別、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆